3SBio Inc
Xiang H. is currently serving as the Australia CEO and Chief Financial Officer at 3SBio Inc., a position held since July 2023. Prior to this role, Xiang H. accumulated extensive experience at J.P. Morgan from June 2013 to July 2023, where responsibilities included Head of Financial Institutions & Government for China and Head of Corporate Finance, alongside serving as Executive Director. Earlier experience includes a position as Associate in Investment Banking at Citi between June 2008 and June 2013.
This person is not in any teams
This person is not in any offices
3SBio Inc
3SBio Inc. is an investment holding company mainly engaged in the the development, production, marketing and sale of pharmaceutical products. The Company's main products include recombinant human thrombopoietin (rhTPO) products, tumor necrosis factor (TNF)αinhibitor products and recombinant human erythropoietin (rhEPO) products. The products are sold under the name of TPIAO, Yisaipu, EPIAO and SEPO. The Company distributes its products within the domestic market and to overseas markets, including Sri Lanka, Dominican Republic and Thailand. The Company's subsidiaries include Collected Mind Limited, Hongkong Sansheng Medical Limited and Shenyang Sunshine Pharmaceutical Co., Ltd. Through its subsidiaries, the Company is engaged in project management and consultation.